Aeterna Zentaris Inc.
(NASDAQ : AEZS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Loading AEZS News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.04%68.550.9%$505.54m
AMGNAmgen Inc.
0.37%163.321.1%$461.64m
BIIBBiogen Inc.
-1.94%271.211.2%$423.43m
CELGCelgene Corporation
0.07%124.051.2%$383.45m
REGNRegeneron Pharmaceuticals, Inc.
5.97%388.492.7%$332.95m
ALXNAlexion Pharmaceuticals, Inc.
0.69%127.781.9%$250.96m
INCYIncyte Corporation
0.09%124.282.6%$247.36m
VRTXVertex Pharmaceuticals Incorporated
0.75%118.301.9%$235.75m
ILMNIllumina, Inc.
0.61%184.863.5%$200.54m
TSROTESARO, Inc.
0.67%147.5914.7%$130.72m
NBIXNeurocrine Biosciences, Inc.
-0.36%53.405.3%$114.24m
BMRNBioMarin Pharmaceutical Inc.
-0.40%95.884.5%$113.09m
KITEKite Pharma, Inc.
-0.68%82.0816.6%$94.29m
AAgilent Technologies, Inc.
-0.70%55.041.5%$93.33m
SRPTSarepta Therapeutics, Inc.
4.44%36.2619.8%$82.73m

Company Profile

Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company that is engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health. The company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. It focuses on the development of Perifosine, Cetrotide, Ozarelix, AEZS-108 and AEZS-130. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Montreal, Canada.